Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06734130 · ClinicalTrials.gov registry record · Phase 2
Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer
A Phase 2 study of Metastatic Castration-Sensitive Prostate Cancer, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Active
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT06734130: Active Phase 2 study of Metastatic Castration-Sensitive Prostate Cancer, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
NCT06734130 is a Phase 2 study of Metastatic Castration-Sensitive Prostate Cancer that is active but no longer recruiting, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 25 participants, below the 559-participant average among 5 other Metastatic Castration-Sensitive Prostate Cancer trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06734130, a Phase 2 study of Metastatic Castration-Sensitive Prostate Cancer, is active but no longer recruiting, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a prospective single center phase IIa open label nonrandomized study, which aims to test the hypothesis that the duration of castration sensitive phase of stage IV prostate cancer can be prolonged with adaptive androgen deprivation therapy (ADT) and Docetaxel.
Primary Outcome
Percentage of patients who remain castration sensitive at 36 months from initiation of LHRH analog for stage IV prostate cancer.
Conditions Studied
Interventions
- DRUG Docetaxel
- DRUG Luteinizing Hormone-Releasing Hormone (LHRH) analog
- DRUG Androgen Receptor Signal Inhibitor (ARSI)
Study Locations (1)
Florida
- Moffitt Caner Center - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2025-01-10 |
| Est. Completion | 2028-11 |
| Phase | Phase 2 |
What the registry record for NCT06734130 still lists
NCT06734130 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 559-participant average among 5 other Metastatic Castration-Sensitive Prostate Cancer trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Metastatic Castration-Sensitive Prostate Cancer appearing as the primary indexed condition, and to 3 interventions - of which Docetaxel is the first listed.
NCT06734130 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT06734130 about?
NCT06734130 is a clinical study titled "Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer". This is a prospective single center phase IIa open label nonrandomized study, which aims to test the hypothesis that the duration of castration sensitive phase of stage IV prostate cancer can be prolonged with adaptive androgen deprivation therapy (ADT) and Docetaxel.
What is the current status of trial NCT06734130?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2025-01-10. Estimated completion is 2028-11.
What conditions does trial NCT06734130 study?
This clinical trial studies the following conditions: Metastatic Castration-Sensitive Prostate Cancer.
What interventions are being tested in trial NCT06734130?
The interventions under investigation include: Docetaxel (DRUG), Luteinizing Hormone-Releasing Hormone (LHRH) analog (DRUG), Androgen Receptor Signal Inhibitor (ARSI) (DRUG).
Who is sponsoring clinical trial NCT06734130?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06734130 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Castration-Sensitive Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy
ACTIVE NOT RECRUITING · Phase 2
-
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
RECRUITING · Phase 3
-
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
RECRUITING · Phase 1
-
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
ACTIVE NOT RECRUITING · Phase 3
-
TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI